Last reviewed · How we verify

Boostrix PolioTM

GlaxoSmithKline · Phase 3 active Biologic

Boostrix Polio is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus.

Boostrix Polio is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, and poliovirus. Used for Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in adolescents and adults.

At a glance

Generic nameBoostrix PolioTM
SponsorGlaxoSmithKline
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

This vaccine contains inactivated toxoids of diphtheria and tetanus, acellular pertussis antigens, and inactivated poliovirus particles. Upon administration, these antigens trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory B cells against these four pathogens. This provides immunological protection against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: